Additionally, research include Wundecyte’s oxygen-producing bandage properties for treatment of full-thickness excisional wounds and partial thickness burns.

The preclinical study funded by the US Department of Defense, will also assess Wundecyte’s ability to prevent scar formation and improve infection control.

Both the companies’ researchers will work together in the study design and investigator meetings.

Oxygen Biotherapeutics chief medical officer Gerald Klein said they believe that providing additional oxygen may help heal wounds, fight infections and decrease scarring.

"Wundecyte, PFC gel, used alone and in combination with a bandage that releases oxygen to the damaged tissue site, may be particularly useful in military applications," Klein said.

"Naturally, if study results are favorable, it may also have applications for civilian injuries as well. We look forward to working closely with HUMC on this important study."